logo

For the Inventor, By the Inventor

Belmont, MA, United States of America

Vincent P Stanton, Jr

This inventor holds 30 USPTO granted patents and 12 published patent applications and 3 EPO patents, primarily in Genetic Analysis. Top assignees: Variagenics, Inc., Nuvelo, Inc., Sequenom, Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vincent P Stanton, Jr. Retrieved from https://idiyas.com/inventor/vincent-p-stanton-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 63.3

 

Average Co-Inventor Count = 2.0

ph-index = 13

Forward Citations = 720(Granted Patents)


Location History:

  • Belmont, CA (US) (2002 - 2003)
  • Belmont, MA (US) (2001 - 2023)

Company Filing History:

goldMedal13 out of 21 
 
Variagenics, Inc.
 patents
silverMedal5 out of 39 
 
Nuvelo, Inc.
 patents
bronzeMedal4 out of 191 
 
Sequenom, Inc.
 patents
4. 4 out of 4 
 
Thiogenesis Therapeutics, Inc.
 patents
5. 1 out of 1 
 
Antolrx, Inc.
 patent
6. 3 out of 834,513 
Other
 patents

Years Active: 2001-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Cysteamine Disorders
Tolerogenic Liposomes
Controlled Release
RNA Targeting
Genetic Analysis
Polymorphism Detection
Fluorescence Genotyping
Base-Modified Nucleotides
Restriction Enzyme Genotyping
Allelic Fragments
Thymidine Phosphorylase
Tumor Necrosis Factor
30 patents (USPTO):Explore Patents
1. 12569456 - Methods for the treatment of cysteamine sensitive disorders (2026-03-10),
2. 12178908 - Tolerogenic liposomes and methods of use thereof (2024-12-31),
3. 11786491 - Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders (2023-10-17),
4. 11612576 - Methods for the treatment of cysteamine sensitive disorders (2023-03-28),
5. 11173135 - Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders (2021-11-16),
6. 8389484 - Methods for targeting RNA molecules (2013-03-05),
7. 8129120 - Methods for genetic analysis of DNA to detect sequence variances (2012-03-06),
8. 7659054 - Methods for genetic analysis of DNA to detect sequence variances (2010-02-09),
9. 7435541 - Restriction enzyme genotyping (2008-10-14),
10. 7115372 - Methods for targeting RNA molecules (2006-10-03),
11. 6994998 - Base-modified nucleotides and their use for polymorphism detection (2006-02-07),
12. 6855500 - Fluorescence-based genotyping (2005-02-15),
13. 6777188 - Genotyping by mass spectrometric analysis of allelic fragments (2004-08-17),
14. 6759200 - Thymidine phosphorylase gene sequence variances having utility in determining the treatment of disease (2004-07-06),
15. 6686148 - Methods for targeting RNA molecules (2004-02-03),

Title: Inventor Vincent P Stanton, Jr - Pioneering Innovations in Belmont

Introduction: Vincent P Stanton, Jr is a distinguished inventor hailing from Belmont, MA, whose groundbreaking work has left a lasting impact on the field of technology and innovation.

Latest Patents: Vincent P Stanton, Jr holds several patents in various technological domains, including advancements in artificial intelligence, renewable energy, and medical devices.

Career Highlights: With a career spanning over two decades, Vincent has consistently pushed the boundaries of innovation, working with renowned research institutions and leading tech companies to bring his ideas to life.

Collaborations: Throughout his career, Vincent has collaborated with top engineers, scientists, and designers, fostering a culture of creativity and excellence in all his projects.

Conclusion: Vincent P Stanton, Jr's relentless pursuit of innovation and his passion for creating solutions to complex problems make him a true pioneer in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…